AR102572A1 - FORMULATION OF STABLE PROTEIN SOLUTION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY - Google Patents
FORMULATION OF STABLE PROTEIN SOLUTION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODYInfo
- Publication number
- AR102572A1 AR102572A1 ARP150103621A ARP150103621A AR102572A1 AR 102572 A1 AR102572 A1 AR 102572A1 AR P150103621 A ARP150103621 A AR P150103621A AR P150103621 A ARP150103621 A AR P150103621A AR 102572 A1 AR102572 A1 AR 102572A1
- Authority
- AR
- Argentina
- Prior art keywords
- high concentration
- formulation
- solution containing
- protein solution
- containing high
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anticuerpos anti-VEGF formulados como composiciones farmacéuticas acuosas, de alta concentración, adecuados para una inyección, preferentemente una inyección intravítrea. Las composiciones farmacéuticas acuosas son útiles para la administración de una alta concentración del ingrediente activo del anticuerpo a un paciente sin altos niveles de agregación de anticuerpo y sin un alto nivel de materia particulada subvisible. Una composición acuosa que comprende un anticuerpo que tiene una concentración de al menos 50 mg/ml. Una composición farmacéutica acuosa que incluye azúcar, un agente de amortiguación y un tensioactivo.Anti-VEGF antibodies formulated as high concentration aqueous pharmaceutical compositions suitable for an injection, preferably an intravitreal injection. Aqueous pharmaceutical compositions are useful for the administration of a high concentration of the active ingredient of the antibody to a patient without high levels of antibody aggregation and without a high level of subvisible particulate matter. An aqueous composition comprising an antibody having a concentration of at least 50 mg / ml. An aqueous pharmaceutical composition that includes sugar, a buffering agent and a surfactant.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076770P | 2014-11-07 | 2014-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102572A1 true AR102572A1 (en) | 2017-03-08 |
Family
ID=58688557
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103539A AR102494A1 (en) | 2014-11-07 | 2015-11-02 | METHODS TO TREAT EYE DISEASES |
| ARP150103621A AR102572A1 (en) | 2014-11-07 | 2015-11-06 | FORMULATION OF STABLE PROTEIN SOLUTION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103539A AR102494A1 (en) | 2014-11-07 | 2015-11-02 | METHODS TO TREAT EYE DISEASES |
Country Status (1)
| Country | Link |
|---|---|
| AR (2) | AR102494A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101861163B1 (en) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | Ophthalmic pharmaceutical composition |
-
2015
- 2015-11-02 AR ARP150103539A patent/AR102494A1/en unknown
- 2015-11-06 AR ARP150103621A patent/AR102572A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR102494A1 (en) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201700096A (en) | STABLE PROTEIN FORMULATION IN SOLUTION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY | |
| CY1122181T1 (en) | PHARMACEUTICAL FORM OF ANTIBODY | |
| CO7111300A2 (en) | Antibody formulation | |
| CL2021001587A1 (en) | Protein solution formulation containing a high concentration of an anti-vegf antibody | |
| NZ702342A (en) | Pharmaceutical formulation | |
| MX2019014666A (en) | Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof. | |
| AR102572A1 (en) | FORMULATION OF STABLE PROTEIN SOLUTION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY | |
| AR130115A2 (en) | STABLE PROTEIN SOLUTION FORMULATION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY | |
| UA123395U (en) | PHARMACEUTICAL COMPOSITION OF NISTATIN IN THE FORM OF ORAL SUSPENSION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |